Abstract
Targeting cancer cells with high specificity is one of the most essential yet challenging goals of tumor therapy. Because different surface receptors, transporters, and integrins are overexpressed specifically on tumor cells, using these tumor cell-specific properties to improve drug targeting efficacy holds particular promise. Targeted fluorescent prodrugs not only improve intracellular accumulation and bioavailability but also report their own localization and activation through real-time changes in fluorescence. In this review, efforts are highlighted to develop innovative targeted fluorescent prodrugs that efficiently accumulate in tumor cells in different organs, including lung cancer, liver cancer, cervical cancer, breast cancer, glioma, and colorectal cancer. The latest progress and advances in chemical design and synthetic considerations in fluorescence prodrug conjugates and how their therapeutic efficacy and fluorescence can be activated by tumor-specific stimuli are reviewed. Additionally, novel perspectives are provided on strategies behind engineered nanoparticle platforms self-assembled from targeted fluorescence prodrugs, and how fluorescence readouts can be used to monitor the position and action of the nanoparticle-mediated delivery of therapeutic agents in preclinical models. Finally, future opportunities for fluorescent prodrug-based strategies and solutions to the challenges of accelerating clinical translation for the treatment of organ-specific tumors are proposed.
| Original language | English |
|---|---|
| Article number | 2207768 |
| Journal | Advanced Science |
| Volume | 10 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - 2023 Jun 2 |
Bibliographical note
Funding Information:S.M., J.H.K., and W.C. contributed equally to this work. This work was supported by the National Science Foundation of China (No. 22174090, G. C.); the Natural Science Basic Research Program of Shaanxi (No. 2022JM-089, Y. L.); Long-term Project of high-level talents innovation in Shaanxi Province (G.C.); the High-end project of National Foreign Expert Program (No. G2021041002L, G. C.); the fellowship of China Postdoctoral Science Foundation (No. 2022M711994, S. M.); Key Laboratory of Emergency and Trauma (Hainan Medical University) Ministry of Education (Grant No. KLET-202010, S. M.); Special Scientific Research Project of Education Department of Shaanxi Provincial Government (No. 21JK0545, S. M.); Young Talent Fund of Xi'an Association for Science and Technology (No. 095920211319, S. M.); National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (CRI Project No. 2018R1A3B1052702, J.S.K.) and by the Ministry of Education (No. 2019H1A2A1074096, J.H.K.). This work was also supported by the US METAvivor Early Career Investigator Award (No. 2018A020560, W.T.), Harvard Medical School/Brigham and Women's Hospital Department Basic Scientist Grant (No. 2420 BPA075, W.T.), Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Innovator Award (No. 113548, W.T.), Center for Nanomedicine Research Fund (No. 2019A014810, W.T.), Nanotechnology Foundation (No. 2022A002721, W.T.), and Farokhzad Family Distinguished Chair Foundation (No. 018129, W.T.). W.T. is also a recipient of the Khoury Innovation Award (No. 2020A003219), and American Heart Association (AHA) Collaborative Sciences Award (No. 2018A004190).
Funding Information:
S.M., J.H.K., and W.C. contributed equally to this work. This work was supported by the National Science Foundation of China (No. 22174090, G. C.); the Natural Science Basic Research Program of Shaanxi (No. 2022JM‐089, Y. L.); Long‐term Project of high‐level talents innovation in Shaanxi Province (G.C.); the High‐end project of National Foreign Expert Program (No. G2021041002L, G. C.); the fellowship of China Postdoctoral Science Foundation (No. 2022M711994, S. M.); Key Laboratory of Emergency and Trauma (Hainan Medical University) Ministry of Education (Grant No. KLET‐202010, S. M.); Special Scientific Research Project of Education Department of Shaanxi Provincial Government (No. 21JK0545, S. M.); Young Talent Fund of Xi'an Association for Science and Technology (No. 095920211319, S. M.); National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (CRI Project No. 2018R1A3B1052702, J.S.K.) and by the Ministry of Education (No. 2019H1A2A1074096, J.H.K.). This work was also supported by the US METAvivor Early Career Investigator Award (No. 2018A020560, W.T.), Harvard Medical School/Brigham and Women's Hospital Department Basic Scientist Grant (No. 2420 BPA075, W.T.), Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Innovator Award (No. 113548, W.T.), Center for Nanomedicine Research Fund (No. 2019A014810, W.T.), Nanotechnology Foundation (No. 2022A002721, W.T.), and Farokhzad Family Distinguished Chair Foundation (No. 018129, W.T.). W.T. is also a recipient of the Khoury Innovation Award (No. 2020A003219), and American Heart Association (AHA) Collaborative Sciences Award (No. 2018A004190).
Publisher Copyright:
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Keywords
- cancer specific targeting
- drug delivery system
- fluorescent prodrug
- nanoparticles
- tumor therapy
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Chemical Engineering(all)
- Materials Science(all)
- Biochemistry, Genetics and Molecular Biology (miscellaneous)
- Engineering(all)
- Physics and Astronomy(all)
